
Supernus Pharmaceuticals announced a 43% year-over-year revenue increase in its key growth products during Q3 2026, driven by ADHD treatment Qelbree and postpartum depression drug ZURZUVAE. The company aims to achieve $125 million in annual cost synergies from its merger with Indivior Pharmaceuticals, enhancing profitability through operational efficiencies. Additionally, ONAPGO, a Parkinson's treatment, secured seven years of FDA orphan drug exclusivity, which along with dual manufacturing sources, is expected to stabilize its growth. Supernus plans to continue expanding its commercial portfolio and market presence into the 2030s with strong cash flow supporting clinical research and sales efforts.
Supernus Pharmaceuticals (SUPN) shares trade at USD 28.61 on Pluang as of Nov 23, 2026 05:21 WIB, up 0.92% in the past day. The stock's market cap stands at $5.94 billion with a 52-week range between $26.16 and $41.83. This trading activity occurs alongside the company's announcement of strong revenue growth and strategic moves to enhance profitability and market presence.